Screener
ANI Pharmaceuticals ANIP Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by ANI Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The source filing: ANI Pharmaceuticals’s 10-Q, filed August 7, 2026. Open the filing →
- Filed
- Aug 7, 2026, 7:01 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001023024-26-000069
FAQ
- What is ANI Pharmaceuticals's long-term debt?
- ANI Pharmaceuticals (ANIP) reported long-term debt of $280.16M in Q2 2026.
- How has ANI Pharmaceuticals's long-term debt changed year-over-year?
- ANI Pharmaceuticals's long-term debt decreased by 7.1% year-over-year, from $301.48M to $280.16M.
- What is the long-term trend for ANI Pharmaceuticals's long-term debt?
- Over 5 years (2020 to 2025), ANI Pharmaceuticals's long-term debt has grown at a 11.1% compound annual growth rate (CAGR), from $172.44M to $291.84M.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about ANI Pharmaceuticals's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude